evipedia.ai
← Back

L-Methylfolate for Health & Longevity

Evidence Review created on 10/22/2026 using AI4L / Opus 5.5

Also known as: L-5-Methyltetrahydrofolate, L-5-MTHF, 5-MTHF, (6S)-5-Methyltetrahydrofolate, Levomefolic Acid, Levomefolate, Levomefolate Calcium, Calcium L-Methylfolate, Methylfolate, Metafolin, Quatrefolic, Deplin

Motivation

L-methylfolate (also called active folate) is the form of vitamin B9 that already circulates in human blood. Ordinary folic acid from fortified foods and many supplements has to be converted by the body before it can be used, while L-methylfolate skips those steps. It supplies the building blocks the body uses to clear a blood compound linked to blood vessel health and to make several brain chemicals.

Interest grew as home genetic tests showed that many people carry a common gene variant that slows this conversion, and as supplement makers began promoting the active form over folic acid. Separately, a doctor-supervised product containing L-methylfolate was studied as an add-on for people whose depression did not respond well to standard antidepressants.

This review examines what human studies show about L-methylfolate for folate status, mood and healthy aging, how its risks compare with those of folic acid, and how product quality and industry funding shape the available evidence.

Benefits - Risks - Protocol - Conclusion

This section lists expert articles, podcasts and commentary that give a high-level overview of L-methylfolate and the folate pathway it belongs to.

Only three items are listed: no further freely accessible high-level overview of L-methylfolate was found; a critical Carlat Psychiatry Report commentary was not listed because its content is behind a subscription paywall.

FoundMyFitness items found were a short clip in which Tim Ferriss and Rhonda Patrick trade anecdotes about MTHFR and methylated B vitamins, a 2015 genetics episode touching on MTHFR among many gene–nutrient pairs, and members-only Aliquot and Q&A sessions on homocysteine and folate forms; the clip and episode lack depth on L-methylfolate and the premium items are paywalled, so none was listed. Only one Huberman Lab item was found, a brief timestamped segment naming L-5-methyltetrahydrofolate within a pain-relief episode; it does not discuss the compound in substantial depth and was not listed. No Lifespan.io content on L-methylfolate or folate supplementation was found.

Grokipedia

  • Levomefolic acid

    An AI-written entry on chemistry, pharmacokinetics, uses and safety; it overstates regulatory status, calling L-methylfolate “approved” for depression, where it is a medical food (physician-supervised nutritional product) (Deplin FC).

Examine

  • Folic Acid (Vitamin B9)

    Examine’s folate page, to which its methylfolate search resolves, grades folate outcomes and flags that L-methylfolate supplements are less stable than folic acid and can deviate widely from labeled content.

ConsumerLab

Systematic Reviews

This section lists systematic reviews and meta-analyses of L-methylfolate for mood, schizophrenia, folate status and the folic acid comparison.

No systematic review or meta-analysis addresses the principal risks of L-methylfolate itself (masking of vitamin B12 deficiency, possible promotion of existing tumors); that side of the trade-off is unrepresented here and relies on folic acid data.

Mechanism of Action

L-methylfolate is the main folate form in food and blood. Synthetic folic acid must first be reduced, partly by DHFR (dihydrofolate reductase, an enzyme that activates folic acid slowly in humans), and then converted by MTHFR before joining this pool; supplemental L-methylfolate bypasses both steps (Pietrzik et al., 2010).

  • One-carbon metabolism (reactions moving single-carbon units): methionine synthase (the B12-dependent enzyme that recycles homocysteine) transfers L-methylfolate’s methyl group to homocysteine, forming methionine and then SAMe (S-adenosylmethionine, the body’s main methyl donor for DNA, protein and neurotransmitter methylation). Without B12, folate becomes trapped as L-methylfolate.
  • Monoamine and nitric oxide pathways: L-methylfolate is proposed to help regenerate BH4 (tetrahydrobiopterin, a cofactor for enzymes producing serotonin, dopamine, norepinephrine and nitric oxide). 5-MTHF improved eNOS (endothelial nitric oxide synthase, the vessel-relaxing enzyme) function in human vessels (Antoniades et al., 2006).
  • Competing view: at equal doses, L-methylfolate and folic acid show comparable physiological activity, bioavailability and absorption (Pietrzik et al., 2010). The proposed advantages of the “active form”, less masking of B12 deficiency and fewer interactions with DHFR-blocking drugs, have not been tested against clinical outcomes.
  • Pharmacology: peak plasma levels arrive 0.5–1.5 hours after a dose; the terminal half-life is about 4–5 hours, while a slow tissue pool turns over across 100 days or more; elimination is urinary and fecal (Beyaz label). It is a nutrient cofactor rather than a receptor-selective drug, distributes to all tissues via folate transporters, and is not metabolized by CYP (cytochrome P450 drug-metabolizing) enzymes.

Historical Context & Evolution

  • Original use: L-methylfolate was first used medically to correct folate deficiency. In 1990, a London trial gave 15 mg methylfolate daily to folate-deficient patients with depression or schizophrenia and reported better recovery than placebo (Godfrey et al., 1990). A 1993 Italian trial found 50 mg/day 5-MTHF and the antidepressant trazodone reduced depressive symptoms similarly in older adults with dementia (Passeri et al., 1993).
  • Commercial formulation: a stable crystalline calcium salt (Metafolin) made the single natural isomer (mirror-image form) practical for supplements (Pietrzik et al., 2010). Pamlab then marketed Deplin as a medical food for depression (NCT00955955; Deplin FC), and the FDA (US Food and Drug Administration) approved Beyaz, an oral contraceptive with levomefolate calcium, in 2010 (Beyaz label).
  • Route into health optimization: the homocysteine hypothesis of vascular and brain aging, consumer genotyping revealing common MTHFR variants, and concern about unmetabolized folic acid drew health-focused adults to the active form.
  • How opinion shifted: large homocysteine-lowering trials with folic acid and B vitamins showed no effect on heart attacks or deaths but a small reduction in strokes (Martí-Carvajal et al., 2017), shifting interest toward targeted uses. For depression, industry-supported positive trials were followed by meta-analyses rating evidence quality as low (Roberts et al., 2018). A WFSBP–CANMAT (World Federation of Societies of Biological Psychiatry and Canadian Network for Mood and Anxiety Treatments) taskforce, whose psychiatrist members sell no supplements but whose lead author discloses nutraceutical-company payments, gave methylfolate a weak recommendation for depression (Sarris et al., 2022).

Expected Benefits

High 🟩 🟩 🟩

Raising Body Folate Status

L-methylfolate reliably raises red blood cell folate, a measure of tissue folate stores that tracks neural tube defect (birth defects of the brain and spine) risk in people. Randomized trials from independent groups agree: Lamers (Bonn), Henderson and Devlin (Vancouver) and Venn (Dunedin) found equal or larger rises than an equal molecular dose of folic acid (Lamers et al., 2006; Henderson et al., 2018; Venn et al., 2003). Homocysteine fell about 15% versus placebo in two of these trials. Most participants were healthy women.

Magnitude: Red blood cell folate 1,951 nmol/L with 1.13 mg/day L-5-MTHF vs 958 nmol/L with placebo after 12 weeks (P, the probability of a chance result, < 0.001) (Henderson et al., 2018).

Medium 🟩 🟩

Add-On Treatment for Antidepressant-Resistant Depression ⚠️ Conflicted

In two trials led by Massachusetts General Hospital and co-sponsored by Pamlab, maker of Deplin, 15 mg/day added to SSRIs (selective serotonin reuptake inhibitors, the commonest antidepressants) outperformed placebo, while 7.5 mg did not (Papakostas et al., 2012). A meta-analysis found a small benefit (Maruf et al., 2022); another graded all evidence low or very low (Roberts et al., 2018). Net reading: a modest, dose-dependent add-on effect, resting largely on one industry-linked research group.

Magnitude: Response RR (relative risk) 1.25 (95% CI, or confidence interval, 1.08–1.46) vs antidepressant alone; symptom SMD (standardized mean difference) −0.38 (−0.59 to −0.17) (Maruf et al., 2022); NNT (number needed to treat) for response about 6 at 15 mg/day (Papakostas et al., 2012).

Lowering Blood Pressure

In a 3-week placebo-controlled trial in 30 healthy postmenopausal women, oral 15 mg/day 5-MTHF lowered night-time blood pressure and markers of oxidative stress (cell damage from reactive oxygen), while placebo changed neither (Cagnacci et al., 2015). The authors linked the fall to reduced oxidative stress. An unblinded randomized trial (participants knew their treatment) of 800 µg L-methylfolate plus methylcobalamin (a vitamin B12 form) lowered blood pressure in dialysis patients with hard-to-control hypertension, but the combination makes it indirect (Salem et al., 2026). Direct evidence is one small, short trial.

Magnitude: Night-time mean and diastolic blood pressure fell by about 5 mmHg on 5-MTHF, while placebo did not change any blood pressure value; not compared between groups (Cagnacci et al., 2015).

Negative Symptoms of Schizophrenia ⭕️ Not Central to Health & Longevity

In a 12-week randomized trial of 55 outpatients on stable antipsychotics, 15 mg/day raised plasma methylfolate and improved total and negative symptom scores versus placebo; cognition did not change (Roffman et al., 2018). The trial was sponsored by Pamlab (NCT01091506). A meta-analysis pooling folate forms found benefit for negative symptoms only (Sakuma et al., 2018). This bears on managing schizophrenia, not on health and longevity in healthy adults.

Magnitude: PANSS (Positive and Negative Syndrome Scale) total improvement versus placebo, standardized effect size d = 0.61 (P = 0.03) (Roffman et al., 2018).

Add-On Treatment for Portal Hypertension in Cirrhosis ⭕️ Not Central to Health & Longevity

In a 90-day placebo-controlled trial in 60 people with cirrhosis (liver scarring) and portal hypertension (raised pressure in the liver’s main vein), 5-MTHF added to propranolol (a beta-blocker, a drug that slows the heart and lowers portal pressure) reduced portal pressure more than propranolol plus placebo (Vukotic et al., 2023). The authors attribute the effect to better nitric oxide availability in liver blood vessels. Evidence is one trial from one group. This bears on managing cirrhosis, not on health and longevity in healthy adults.

Magnitude: Hepatic venous pressure gradient (a measure of portal pressure) fell by a median 20% with 5-MTHF plus propranolol vs 12.5% with placebo plus propranolol (P = 0.028) (Vukotic et al., 2023).

Low 🟩

Stroke Prevention

Indirect: trials tested folic acid, not L-methylfolate. Adding 0.8 mg folic acid to enalapril (a blood pressure drug) reduced first strokes in Chinese adults with hypertension (Huo et al., 2015); a Cochrane review found a small stroke reduction across B-vitamin trials (Martí-Carvajal et al., 2017).

Magnitude: First stroke 2.7% vs 3.4%; HR (hazard ratio) 0.79 (95% CI 0.68–0.93) with enalapril plus folic acid vs enalapril alone (Huo et al., 2015).

Survival and Cardiovascular Events ⚠️ Conflicted

Intravenous 5-MTHF in dialysis patients was linked to longer survival than oral folic acid (Cianciolo et al., 2008); route and population differ. A Cochrane review of B-vitamin trials found no effect on heart attacks or death (Martí-Carvajal et al., 2017). Net reading: no evidence that oral L-methylfolate extends survival.

Magnitude: Survival 36.2 vs 26.1 months with intravenous 5-MTHF vs oral folic acid (P = 0.003) (Cianciolo et al., 2008); death from any cause 11.7% vs 12.3%, RR 1.01 (95% CI 0.96–1.06) for B vitamins vs placebo (Martí-Carvajal et al., 2017).

Cognitive Aging ⚠️ Conflicted

Indirect evidence from folic acid: three years of 0.8 mg/day improved memory in adults with high homocysteine (Durga et al., 2007), but a meta-analysis of 11 B-vitamin trials found no cognitive effect (Clarke et al., 2014). Net reading: no reliable cognitive benefit shown.

Magnitude: Memory z score (standardized score) difference 0.132 (95% CI 0.032–0.233) vs placebo (Durga et al., 2007); global cognition z score difference 0.00 (95% CI −0.05 to 0.06) (Clarke et al., 2014).

Diabetic Nerve Pain ⭕️ Not Central to Health & Longevity

Indirect: tested only in Metanx, combining 3 mg L-methylfolate with methylcobalamin and pyridoxal phosphate (vitamin B12 and B6 forms). In a Pamlab-sponsored 24-week trial in 214 people with type 2 diabetes, symptoms improved but nerve sensitivity did not (Fonseca et al., 2013). This bears on diabetic complications.

Magnitude: Neuropathy symptom score improved significantly versus placebo at week 24 (P = .033), with no change in vibration threshold; the abstract reports no between-group figure (Fonseca et al., 2013).

Pregnancy Outcomes After Prior Loss ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A meta-analysis of low-quality trials linked active folate with more pregnancies after prior adverse outcomes (Xie et al., 2025); a 220-woman randomized trial found no miscarriage difference versus folic acid (Hekmatdoost et al., 2015). This bears on fertility. Net reading: no proven advantage over folic acid.

Magnitude: Higher subsequent pregnancy rate with active folate than folic acid in women with prior adverse pregnancy outcomes (three trials, P = .0005); the review’s text reports only P values for this outcome (Xie et al., 2025). Ongoing pregnancy 36 of 69 with 5-MTHF vs 27 of 66 with folic acid; abortion rates did not differ significantly (Hekmatdoost et al., 2015).

Speculative 🟨

Endothelial Function

Indirect: 5-MTHF was infused, not taken orally. Infusion restored blood vessel relaxation in inherited high cholesterol (Verhaar et al., 1998) and bypass-surgery patients (Antoniades et al., 2006), an unvalidated biomarker.

Avoiding Unmetabolized Folic Acid

Using 5-MTHF instead of folic acid lowers unmetabolized folic acid (unconverted folic acid in blood) (Frye & Rossignol, 2026). This is an unvalidated biomarker, and no harm from it is established.

Methylation Support and Biological Aging

The basis is mechanistic only. L-methylfolate feeds SAMe production for DNA methylation, but no human study has measured epigenetic aging (age-related DNA methylation change) or lifespan with it.

Benefit-Modifying Factors

  • MTHFR C677T genotype (a common variant reducing enzyme activity): with racemic (mixed-isomer) MTHF, TT carriers (two variant copies) had the largest but non-significant homocysteine drop (Fohr et al., 2002), yet 5-MTHF outperformed folic acid on plasma folate in both genotypes (Prinz-Langenohl et al., 2009).
  • Baseline folate and homocysteine: benefits concentrate in people who start low; methylfolate helped folate-deficient psychiatric patients (Godfrey et al., 1990), and B-vitamin slowing of brain atrophy was largest with homocysteine above 13 µmol/L (Smith et al., 2010).
  • Obesity and inflammation: in a post hoc analysis (one not planned before the trial), depression benefit was larger with body mass index of 30 or more and high CRP (C-reactive protein, an inflammation marker) (Shelton et al., 2015).
  • Vitamin B12 status: L-methylfolate needs vitamin B12 to release its methyl group, so B12 deficiency blunts any benefit.
  • Sex: folate-status trials enrolled mostly or only women (Lamers et al., 2006); no sex difference in depression response has been reported, and data in men are thinner.
  • Age: folic acid absorption was lower in middle-aged than young adults (de Meer et al., 2005); in adults aged 50–65, 5-MTHF and folic acid lowered homocysteine similarly (Sicińska et al., 2018).
  • Pre-existing conditions: clinical benefits appear in studied conditions, such as antidepressant-resistant depression (Papakostas et al., 2012) and schizophrenia (Roffman et al., 2018); healthy adults gain mainly folate status.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event attributable to L-methylfolate has been shown in controlled trials from more than one independent research group.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial or comparison-group study has documented a harm from L-methylfolate itself; the main concerns rest on folic acid data or labeling.

Low 🟥

Masking of Vitamin B12 Deficiency

The FDA-approved levomefolate label warns that folates may mask B12 deficiency (Beyaz label). Indirect folic acid data: high folate in seniors with low B12 was linked to more anemia and cognitive impairment (Morris et al., 2007). L-methylfolate needs B12 to act, so may mask less (Pietrzik et al., 2010).

Magnitude: In older adults with low B12, high serum folate was associated with anemia (OR, or odds ratio, 3.1; 95% CI 1.5–6.6) and cognitive impairment (OR 2.6; 1.1–6.1) (Morris et al., 2007).

Promotion of Existing Colorectal Growths ⚠️ Conflicted

Indirect: folic acid, not L-methylfolate. 1 mg/day folic acid was associated with more advanced colorectal adenomas (precancerous polyps) at later follow-up, of borderline significance (Cole et al., 2007); a 50,000-person meta-analysis found no cancer increase (Vollset et al., 2013). Net reading: overall cancer risk not raised.

Magnitude: Advanced lesions 11.6% vs 6.9% with placebo, RR 1.67 (95% CI 1.00–2.80) (Cole et al., 2007); overall cancer 1,904 vs 1,809 cases, RR 1.06 (95% CI 0.99–1.13) (Vollset et al., 2013).

Mild Gastrointestinal and Sleep Complaints ⚠️ Conflicted

An open-label study (all participants knew their treatment) reported insomnia and irritability in single patients (Siddique et al., 2025). In the 15 mg/day randomized trial, adverse events were no more frequent than with placebo (Papakostas et al., 2012; NCT00955955). Net reading: no excess risk.

Magnitude: Gastrointestinal events 7/42 (17%) on 15 mg/day vs 8/54 (15%) on placebo; sleep complaints 1/42 vs 3/54; no serious events in either group (NCT00955955).

Mood Activation (Agitation or Mania) ⚠️ Conflicted

A case series described agitation, possibly mania, in three patients starting L-methylfolate, perhaps via monoamine synthesis (Sethness & Miller, 2020). In a 10-patient open bipolar registry, mean mania scores did not rise on 15 mg/day (Nierenberg et al., 2017). Net reading: rare mood activation is possible, including without bipolar disorder.

Magnitude: Young Mania Rating Scale score 3.2 before vs 2.7 after 6 weeks in 10 patients (no control group) (Nierenberg et al., 2017); the case series reports no rate.

Speculative 🟨

Accumulation of the Unnatural 6R Isomer

Racemic (mixed-isomer) 5-MTHF products contain a non-natural 6R form that persisted in blood a week after one dose (Willems et al., 2004). Harm is unproven; the basis is pharmacokinetic only.

Risk-Modifying Factors

  • Vitamin B12 status: low B12 (below 148 pmol/L, or methylmalonic acid above 210 nmol/L) is the main amplifier: in seniors with low B12, high folate was linked to more anemia and cognitive impairment (Morris et al., 2007).
  • Older age: B12 deficiency is common in seniors, raising masking risk; the folate–B12 imbalance associations came from seniors (Morris et al., 2007).
  • History of colorectal adenoma: the adenoma signal came from people with prior polyps (Cole et al., 2007).
  • MTHFR genotype: no evidence shows that MTHFR variants change the side-effect profile of L-methylfolate.
  • Sex and reproductive status: women planning pregnancy face the stakes of neural tube defects, where trials and guidelines tested folic acid rather than L-methylfolate.
  • Epilepsy treated with anticonvulsants (seizure medicines): folates may reduce phenytoin’s effect (Beyaz label).
  • Bipolar disorder: agitation, with possible mania, has been reported in published cases, including one patient with bipolar disorder (Sethness & Miller, 2020).

Key Interactions & Contraindications

Prescription drugs

  • Methotrexate (rheumatology and oncology doses): caution; folates may reduce its effect (Beyaz label), and a psoriasis flare followed adding L-methylfolate (Nazarian & Lamb, 2017). Consequence: loss of disease control. Mitigation: use only with prescriber agreement.
  • Anticonvulsants (seizure medicines; phenytoin, fosphenytoin, carbamazepine, phenobarbital, primidone, valproate): monitor; folates may lower phenytoin’s effect, and these drugs deplete folate (Beyaz label). Consequence: breakthrough seizures. Mitigation: drug levels checked after starting.
  • Antifolate antimicrobials (drugs that block folate use in microbes; pyrimethamine, trimethoprim): caution; folates may reduce pyrimethamine’s effect (Beyaz label); trimethoprim (theoretical). Consequence: treatment failure. Mitigation: prescriber coordination.
  • Antifolate and fluoropyrimidine (cancer drugs that block DNA building-block production) chemotherapy (pemetrexed, pralatrexate, 5-fluorouracil, capecitabine): avoid (theoretical) unless oncologist-directed. Consequence: reduced effect or added toxicity, as folates modify these drugs’ activity.
  • SSRIs and SNRIs (serotonin-norepinephrine reuptake inhibitors; sertraline, escitalopram, fluoxetine, venlafaxine, duloxetine): monitor; additive, intended; no excess adverse events with SSRIs in trials (Papakostas et al., 2012); SNRIs untested (theoretical). Consequence: enhanced antidepressant response. Mitigation: mood monitoring.
  • Methylphenidate: caution; adults on L-methylfolate needed higher methylphenidate doses without added benefit (Surman et al., 2019). Consequence: possibly reduced stimulant efficacy.
  • Oral contraceptives (drospirenone/ethinyl estradiol): no interaction; absorption of either was unchanged in a Bayer-run study (Blode et al., 2012).
  • Folate-depleting drugs (sulfasalazine, cholestyramine, metformin): monitor; sulfasalazine and cholestyramine reduce folate (Beyaz label); metformin lowers B12 (theoretical masking). Consequence: lower folate or hidden B12 deficiency. Mitigation: dosing separated from cholestyramine by 4 hours; B12 checked.
  • Nitrous oxide anesthesia: caution (theoretical); it inactivates vitamin B12, trapping folate as L-methylfolate. Consequence: functional folate and B12 deficiency. Mitigation: anesthetist informed in advance.

Over-the-counter drugs

  • Acid-reducing drugs (omeprazole, esomeprazole, famotidine): monitor (theoretical); long-term use lowers B12 absorption. Consequence: B12 deficiency hidden by folate. Mitigation: periodic B12 testing.

Supplements

  • Folic acid (multivitamins, fortified foods): monitor; additive total folate. Consequence: higher combined intake and unmetabolized folic acid. Mitigation: all sources counted.
  • Vitamin B12, vitamin B6 and riboflavin: none harmful (additive, beneficial); B12 is required for L-methylfolate to work, and L-methylfolate combined with B12 and B6 forms lowered homocysteine versus placebo (Fonseca et al., 2013); riboflavin’s MTHFR support is theoretical. Consequence: further homocysteine lowering.
  • SAMe, 5-HTP (5-hydroxytryptophan, a serotonin precursor), St John’s wort: caution (theoretical); additive serotonergic and mood effects. Consequence: agitation or mood activation. Mitigation: agents added one at a time.
  • Betaine (trimethylglycine) and choline: additive (theoretical) methyl-donor effects on homocysteine; no harm expected. Consequence: further homocysteine lowering.

Other interventions

  • Heavy alcohol intake: monitor; alcohol impairs folate absorption and metabolism (theoretical for L-methylfolate). Consequence: lower folate status despite supplementation.

Populations who should avoid L-Methylfolate:

  • People with untreated vitamin B12 deficiency (serum B12 below 148 pmol/L or methylmalonic acid above 210 nmol/L, per Morris et al., 2007) until B12 is corrected, because folates may mask the deficiency (Beyaz label)
  • People receiving methotrexate, pemetrexed or other antifolate cancer therapy, unless the treating oncologist directs folate use, because folates may reduce antifolate effects (Beyaz label)
  • People with bipolar disorder using high-dose (15 mg/day) L-methylfolate, the dose in published case reports of agitation and possible mania (Sethness & Miller, 2020)
  • People with known hypersensitivity to product ingredients

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Vitamin B12 check before starting: serum B12 and methylmalonic acid are measured first, and values below 148 pmol/L or above 210 nmol/L are corrected before use (Morris et al., 2007). Prevents masked B12 deficiency.
  • Pairing with vitamin B12: L-methylfolate is commonly combined with 500–1,000 µg/day B12, as in combination products. Prevents folate trapping and masking of B12 deficiency.
  • Lowest effective dose: 0.4–1.13 mg/day raised folate status in trials (Lamers et al., 2006; Henderson et al., 2018); 15 mg/day is reserved for supervised depression use. Limits gastrointestinal complaints and any high-dose folate risk.
  • Single-isomer products: labels state L-, (6S)- or levomefolate rather than racemic 5-MTHF. Prevents accumulation of the 6R isomer (Willems et al., 2004).
  • Colorectal screening: people with prior adenomas maintain colonoscopy schedules and avoid stacking high-dose folates. Reduces the risk from possible adenoma promotion.
  • Prescriber coordination: prescribers of anticonvulsants, methotrexate or stimulants are informed, and phenytoin levels are rechecked within 2–4 weeks. Prevents loss of drug efficacy.
  • Mood monitoring in bipolar disorder: use stops and evaluation is sought if reduced sleep need or racing thoughts appear. Mitigates reported mood activation.
  • Third-party-tested products: some 5-MTHF supplements fell outside label tolerance (Žmitek et al., 2021). Prevents underdosing from degraded product.

Therapeutic Protocol

Doses below are cited to their sources; other parameters without a citation (timing, splitting, titration, duration) reflect common practice.

  • Folate-status dose: 0.416 mg/day [6S]-5-MTHF (Lamers et al., 2006) to 1.13 mg/day (Henderson et al., 2018); Beyaz supplies 0.451 mg levomefolate calcium daily (Beyaz label).
  • Homocysteine-focused dose: as little as 113 µg/day lowered homocysteine versus placebo (Venn et al., 2003); 208 µg/day matched 416 µg/day (Lamers et al., 2004).
  • Depression add-on: 15 mg/day with an SSRI; 7.5 mg/day was not superior to placebo (Papakostas et al., 2012). Popularized by Pamlab’s Deplin and the Massachusetts General Hospital group (Papakostas, Fava).
  • Low-dose depression alternative: 800 µg/day added to antidepressants in an open-label trial (Siddique et al., 2025).
  • Practitioner approach: Chris Kresser suggests 600–800 µg/day folate as 5-MTHF when planning pregnancy, and diet alone for men and older women (Kresser, 2012).
  • Competing approach, folic acid: the US Preventive Services Task Force, a federal panel without revenue from either form, recommends at least 0.4 mg/day folic acid for women of childbearing age (Beyaz label); the form tested in outcome trials.
  • Combination products: 3 mg L-methylfolate, 2 mg methylcobalamin and 35 mg pyridoxal phosphate daily in neuropathy (Fonseca et al., 2013).
  • Time of day: morning or with the antidepressant is common; absorption does not depend on timing, and food is not required.
  • Half-life and single dosing: plasma half-life is 4–5 hours, but tissue stores persist for 100+ days (Beyaz label), so one daily dose suffices; splitting offers no shown advantage.
  • MTHFR genotype: 677TT carriers showed a non-significant trend toward the most homocysteine lowering with racemic MTHF (Fohr et al., 2002), but no trial shows genotype-guided dosing improves outcomes.
  • Sex: the federal recommendation for women of reproductive potential is at least 0.4 mg/day folic acid (Beyaz label); most dosing data come from women, and men lack sex-specific data.
  • Age: older adults check B12 first, given age-related absorption decline and higher masking risk.
  • Baseline biomarkers: high homocysteine or low red blood cell folate favors use; in depression, body mass index of 30 or more with high CRP predicted larger response (Shelton et al., 2015).
  • Pre-existing conditions: depression (Papakostas et al., 2012) and schizophrenia (Roffman et al., 2018) trials used 15 mg/day orally; dialysis patients received 50 mg intravenously per session (Cianciolo et al., 2008), a clinic-only route.

Discontinuation & Cycling

  • Lifelong or short-term: nutritional use for folate status is usually ongoing; depression add-on use has been studied for 60 days and continued open-label for 12 months (Zajecka et al., 2016).
  • Withdrawal effects: none have been reported; stopping returns folate status slowly toward baseline because tissue stores turn over across about 100 days (Beyaz label).
  • Tapering: no taper is pharmacologically needed; when used for depression, stopping is usually coordinated with the prescriber to watch for relapse.
  • Pregnancy: if a levomefolate-containing contraceptive is stopped because of pregnancy, folate supplementation is maintained (Beyaz label).
  • Cycling: no evidence supports cycling; tolerance has not been described, and continuous use was studied in all trials.

Sourcing and Quality

  • Salt forms: the calcium salt (Metafolin) was used in 9 of 11 trials in one meta-analysis (Xie et al., 2025); a glucosamine salt (Quatrefolic) is also sold. Both supply the natural (6S) isomer.
  • Racemic products: labels reading only “5-MTHF” or “(6R,S)” may contain the non-natural 6R isomer, which persists in blood (Willems et al., 2004).
  • Stability and label accuracy: 5-MTHF degrades more readily than folic acid; some tested 5-MTHF supplements fell outside the 80–150% label tolerance (Žmitek et al., 2021). Cool, dry storage and in-date products help.
  • Third-party testing: USP (United States Pharmacopeia), NSF International or ConsumerLab verification indicates independently tested folate content.
  • Medical food versus supplement: Deplin (Alfasigma) is marketed as a prescribed medical food (Deplin FC); over-the-counter supplements contain the same active compound at lower cost.
  • Reputable brands: Thorne, Pure Encapsulations, Solgar, Designs for Health and Metabolic Maintenance are named by Kresser as using 5-MTHF (Kresser, 2012); Life Extension and Jarrow also sell L-methylfolate.
  • Label units: US labels often state folate as DFE (dietary folate equivalents), a larger number than the milligram content.

Practical Considerations

  • Time to effect: plasma folate plateaus by about 12 weeks, while red blood cell folate had not plateaued by 24 weeks (Lamers et al., 2006); depression trials assessed response after 30-day periods (Papakostas et al., 2012).
  • Common pitfalls: stacking several folate sources, ignoring vitamin B12, buying racemic or degraded products, and assuming an MTHFR result alone justifies high doses.
  • Regulatory status: in the US, L-methylfolate is sold as a dietary supplement and as Deplin, a medical food (Deplin FC) under FDA’s medical-food framework (FDA medical foods guidance); levomefolate is an approved ingredient of Beyaz (Beyaz label).
  • Cost and payer incentives: branded medical foods cost far more than generic folic acid; insurers and national health systems therefore have a structural incentive to favor folic acid, a potential bias in coverage decisions and guideline formation.
  • Interpreting marketing: the Deplin site cites up to 84% symptom reduction (Deplin FC); this is manufacturer promotion, not an independent estimate.

Interaction with Foundational Habits

  • Sleep: none expected; in the 15 mg/day trial, sleep complaints occurred in 1 of 42 on L-methylfolate versus 3 of 54 on placebo (NCT00955955). If insomnia appears, morning dosing is a common practical adjustment.
  • Nutrition: direct and potentiating; leafy greens, legumes and liver supply natural folates (Kresser, 2012), and fortified grains add folic acid. Animal foods or supplements supply the vitamin B12 that L-methylfolate needs; vegans rely on supplements or fortified foods for B12.
  • Exercise: none known; no study has tested L-methylfolate for training adaptations, and no timing relative to workouts is required.
  • Stress management: indirect; via proposed support of monoamine synthesis, L-methylfolate is studied as an add-on to antidepressants (Papakostas et al., 2012), not as a replacement for psychotherapy, sleep or other stress-reduction practices.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes vitamin B12 adequacy, folate status and homocysteine so that masking of B12 deficiency can be excluded and any later change attributed to supplementation. Depression symptoms are also scored at baseline when L-methylfolate is used as an add-on to antidepressants. A complete blood count provides a reference for later red cell size changes.

Ongoing monitoring follows a set cadence: homocysteine and plasma folate at 8–12 weeks, red blood cell folate at 12–24 weeks because it rises slowly, then vitamin B12, folate and homocysteine every 6–12 months. For depression use, symptom scores are repeated every 4 weeks during the first 3 months, then every 3 months. Anyone taking phenytoin rechecks drug levels within 2–4 weeks of starting.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum vitamin B12 with MMA B12 at or above 148 pmol/L and MMA at or below 210 nmol/L (Morris 2007 cutoffs) Safety check: low B12 stops or delays use MMA: methylmalonic acid, a B12-dependent metabolite. Source: Morris et al., 2007. Conventional B12 reference range roughly 148–590 pmol/L and MMA roughly 70–270 nmol/L, varying by laboratory; MMA confirms borderline B12; no fasting needed
Red blood cell folate Above 906 nmol/L (400 ng/mL) (WHO cutoff for neural tube defect prevention) Expected to rise; tracks tissue folate WHO: World Health Organization. Source: Cordero et al., 2015. Conventional reference range about 140–600 ng/mL (about 317–1,360 nmol/L), varying by laboratory; rises slowly over 12–24+ weeks
Plasma total homocysteine About 5–15 µmol/L (standard reference range) Expected to fall Fasting morning sample; pair with B12 and folate; rises with kidney impairment
MCV in a complete blood count 80–100 fL (standard reference range) Safety check: rising MCV with normal folate suggests hidden B12 deficiency MCV: mean corpuscular volume (average red cell size). Pair with B12 and MMA; no fasting needed
PHQ-9 depression score (depression add-on use only) No established target; track change from the individual’s own baseline Expected to fall if the add-on works PHQ-9: Patient Health Questionnaire-9 (a 9-item depression questionnaire). Repeat every 4 weeks initially; scored by the patient or clinician

Qualitative markers

  • Mood stability and resilience, especially in depression add-on use
  • Energy levels and fatigue
  • Cognitive clarity and focus
  • Sleep quality and any new insomnia or restlessness
  • Tingling, numbness or balance changes (possible unmasked B12 deficiency)
  • Gastrointestinal comfort

Emerging Research

  • CSPPT2 stroke trial: 24,000 hypertensive adults with MTHFR 677TT receive amlodipine (a blood pressure drug) alone, with folic acid, or with folic acid plus 0.4 mg/day 5-MTHF; endpoint first ischemic stroke, completion 2029 (NCT04974151); sponsor Shenzhen Ausa Pharmed. Positive: supports folate for stroke, and 5-MTHF if its arm separates. Null: weakens the stroke rationale.
  • PREFACE preconception trial: 272 women randomized to 0.625 mg/day (6S)-5-MTHF or 0.6 mg folic acid, primary endpoint red blood cell folate, not yet recruiting, completion 2030 (NCT06641245). Positive: supports 5-MTHF as a folic acid substitute. Null: favors folic acid.
  • Fatty liver trial: 44 adults with metabolic dysfunction-associated fatty liver receive 800 µg/day 5-MTHF or placebo for 90 days, measuring folate, homocysteine and inflammatory gene expression; not yet recruiting, completion 2027 (NCT07740109). Positive: suggests a metabolic-liver role. Null: limits claims beyond folate status.
  • Unreported depression trial: a 57-participant University of Florida study of 15 mg/day L-methylfolate for 90 days in depression was completed in 2023, no results posted (NCT02133898).
  • Cognitive decline synthesis: a registered systematic review protocol will pool methylfolate trials on cognitive decline and dementia (Prado et al., 2023), which could strengthen or weaken the indirect cognitive case.
  • Biomarker-guided depression use: obesity and inflammation predicted response in post hoc analyses (Shelton et al., 2015); prospective confirmation is still missing and could narrow or widen use.
  • Unmetabolized folic acid: reviewers found no proven harm from unmetabolized folic acid (Frye & Rossignol, 2026); outcome studies could weaken or strengthen the main rationale for choosing L-methylfolate over folic acid.

Conclusion

L-methylfolate is the ready-to-use folate form circulating in the body. Its most solid benefit is raising blood folate at least as well as ordinary folic acid, which also lowers a blood marker linked to vessel health. As an add-on for depression not fully helped by standard antidepressants, it shows a modest effect at high doses, but most of that evidence comes from one research group working with the product’s maker, and independent reviews rate its quality as low.

For heart health, brain aging and lifespan, the picture is mostly borrowed from folic acid studies, which suggest a small reduction in strokes but no clear effect on heart attacks, memory or survival; one small trial hints at lower blood pressure. The claimed advantage for carriers of a slower folate-processing gene variant has not been shown to change health outcomes.

The main risks are hiding a vitamin B12 deficiency and, based on folic acid data, a possible effect on existing bowel polyps; side effects in trials were no more common than with placebo. Product quality varies; makers and sellers profit from the active form, while payers have a cost reason to prefer folic acid. A psychiatric guideline group, whose members sell no supplements but whose lead author reports industry payments, gave only a weak endorsement for depression, and a federal panel without a stake in either form backs folic acid before pregnancy. For health-focused adults, L-methylfolate is a well-tolerated way to secure folate status, with the larger longevity claims still unproven.

Top - Benefits - Risks - Protocol